NASDAQ:MAZE Maze Therapeutics Q2 2025 Earnings Results & Report $27.48 +1.25 (+4.77%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$27.15 -0.33 (-1.20%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Maze Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.77 versus the -$0.79 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeAfter Market ClosesConference Call4:00 PM ET Maze Therapeutics EPS ResultsActual EPS-$0.77Consensus EPS -$0.79Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate3 of last 7 quartersMaze Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$12.50 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Maze Therapeutics Q2 2025 Earnings FAQ Did Maze Therapeutics beat earnings estimates for Q2 2025? Maze Therapeutics (NASDAQ:MAZE) reported earnings of -$0.77 per share for Q2 2025, beating the consensus estimate of -$0.79. The report was announced on Tuesday, August 12, 2025. Maze Therapeutics Earnings HeadlinesReviewing Nektar Therapeutics (NASDAQ:NKTR) and Maze Therapeutics (NASDAQ:MAZE)October 13 at 8:17 AM | americanbankingnews.comMAZE Stock Gets Increased EPS Forecast from HC WainwrightOctober 7, 2026 | americanbankingnews.comElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation. | Paradigm Press (Ad)Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026October 6, 2026 | globenewswire.comMaze Therapeutics, Inc. (MAZE) Interactive Stock Chart - Yahoo FinanceOctober 6, 2026 | finance.yahoo.comResearch Analysts Set Expectations for MAZE Q2 EarningsOctober 6, 2026 | americanbankingnews.comSee More Maze Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maze Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maze Therapeutics and other key companies, straight to your email. Email Address About Maze TherapeuticsMaze Therapeutics (NASDAQ:MAZE) is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease. Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles. The company is also researching additional programs for genetically defined diseases, including conditions associated with kidney disorders. Maze does not currently have an approved commercial product. Founded in 2017, Maze Therapeutics is headquartered in South San Francisco, California. The company is led by President and Chief Executive Officer Jason Coloma, Ph.D., and conducts research and clinical development aimed at serving patients with serious diseases in the United States and other global markets.View Maze Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
